Your browser doesn't support javascript.
loading
Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain.
Legan, Emily R; Liu, Yi; Arce, Nicholas A; Parker, Ernest T; Lollar, Pete; Zhang, X Frank; Li, Renhao.
Afiliación
  • Legan ER; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.
  • Liu Y; Department of Bioengineering, Lehigh University, Bethlehem, PA.
  • Arce NA; Department of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA.
  • Parker ET; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.
  • Lollar P; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.
  • Zhang XF; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA.
  • Li R; Department of Biomedical Engineering, University of Massachusetts Amherst, Amherst, MA.
Blood ; 141(10): 1221-1232, 2023 03 09.
Article en En | MEDLINE | ID: mdl-36580664
Type 2B von Willebrand disease (VWD) is an inherited bleeding disorder in which a subset of point mutations in the von Willebrand factor (VWF) A1 domain and recently identified autoinhibitory module (AIM) cause spontaneous binding to glycoprotein Ibα (GPIbα) on the platelet surface. All reported type 2B VWD mutations share this enhanced binding; however, type 2B VWD manifests as variable bleeding complications and platelet levels in patients, depending on the underlying mutation. Understanding how these mutations localizing to a similar region can result in such disparate patient outcomes is essential for detailing our understanding of VWF regulatory and activation mechanisms. In this study, we produced recombinant glycosylated AIM-A1 fragments bearing type 2B VWD mutations and examined how each mutation affects the A1 domain's thermodynamic stability, conformational dynamics, and biomechanical regulation of the AIM. We found that the A1 domain with mutations associated with severe bleeding occupy a higher affinity state correlating with enhanced flexibility in the secondary GPIbα-binding sites. Conversely, mutation P1266L, associated with normal platelet levels, has similar proportions of high-affinity molecules to wild-type (WT) but shares regions of solvent accessibility with both WT and other type 2B VWD mutations. V1316M exhibited exceptional instability and solvent exposure compared with all variants. Lastly, examination of the mechanical stability of each variant revealed variable AIM unfolding. Together, these studies illustrate that the heterogeneity among type 2B VWD mutations is evident in AIM-A1 fragments.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor de von Willebrand / Enfermedad de von Willebrand Tipo 2 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor de von Willebrand / Enfermedad de von Willebrand Tipo 2 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos